SCD and prostate carcinoma: Prostate cancer and other tumor types have also been shown to have upregulated SCD1 expression or activity, which may aid in the development of cancer by stimulating the AKT signaling pathway or by blocking AMPK and GSK3, which, in turn, promotes downstream β-catenin activity and triggers associated tumor growth signals [167].